NASDAQ:IKT - Nasdaq - US45719W2052 - Common Stock - Currency: USD
1.77
-0.07 (-3.8%)
The current stock price of IKT is 1.77 USD. In the past month the price decreased by -16.11%. In the past year, price decreased by -2.21%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.84 | 323.71B | ||
AMGN | AMGEN INC | 13.09 | 146.07B | ||
GILD | GILEAD SCIENCES INC | 13.87 | 133.56B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
ONC | BEIGENE LTD-ADR | 6.17 | 26.10B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
NTRA | NATERA INC | N/A | 20.94B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
BIIB | BIOGEN INC | 7.95 | 18.43B |
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Atlanta, Georgia and currently employs 15 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
INHIBIKASE THERAPEUTICS INC
3350 Riverwood Parkway Se, Suite 1900
Atlanta GEORGIA 30339 US
CEO: Milton H. Werner
Employees: 9
Phone: 16783923419
The current stock price of IKT is 1.77 USD. The price decreased by -3.8% in the last trading session.
The exchange symbol of INHIBIKASE THERAPEUTICS INC is IKT and it is listed on the Nasdaq exchange.
IKT stock is listed on the Nasdaq exchange.
7 analysts have analysed IKT and the average price target is 8.16 USD. This implies a price increase of 361.02% is expected in the next year compared to the current price of 1.77. Check the INHIBIKASE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INHIBIKASE THERAPEUTICS INC (IKT) has a market capitalization of 131.58M USD. This makes IKT a Micro Cap stock.
INHIBIKASE THERAPEUTICS INC (IKT) currently has 9 employees.
INHIBIKASE THERAPEUTICS INC (IKT) has a support level at 1.41 and a resistance level at 1.79. Check the full technical report for a detailed analysis of IKT support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IKT does not pay a dividend.
INHIBIKASE THERAPEUTICS INC (IKT) will report earnings on 2025-08-12.
INHIBIKASE THERAPEUTICS INC (IKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.98).
The outstanding short interest for INHIBIKASE THERAPEUTICS INC (IKT) is 2.44% of its float. Check the ownership tab for more information on the IKT short interest.
ChartMill assigns a fundamental rating of 3 / 10 to IKT. IKT has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months IKT reported a non-GAAP Earnings per Share(EPS) of -1.98. The EPS increased by 40.72% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -38.77% | ||
ROE | -42.63% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to IKT. The Buy consensus is the average rating of analysts ratings from 7 analysts.